Fuan Pharmaceutical released its 2026 interim report. The company's total operating revenue was 839 million yuan, down 8.82% from the same period last year. Net profit attributable to the parent company was 95.7748 million yuan, down 15.33% year-on-year. Net cash inflow from operating activities was 184 million yuan. The company's asset-liability ratio was 21.70%, gross margin was 39.59%, ROE was 2.18%, and diluted earnings per share was 0.08 yuan. The number of shareholders was 35,900, and the top ten shareholders held 31.96% of total share capital.
Fuan Pharmaceutical Group CoNet profit fell 15.33% year-on-year in interim report.
